Zuvamor FC Tablets
PDF Leaflet Revision Date: 23 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce cardiovascular event risk and treat hypercholesterolaemia.
Dosage (summary)
Start at 5 mg once daily; adjust based on response.
Onset of Action / Duration
Onset: 1 week, Duration: 4 weeks for max response
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Asian patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Ciclosporin
- Protease inhibitors
- Gemfibrozil
- Fusidic acid
Contraindications
- Active liver disease
- Severe renal impairment
- Myopathy
- Pregnancy
- Lactation
Common side effects
- Myalgia
- Headache
- Dizziness
- Constipation
- Nausea
Counselling Points
- Report muscle pain or weakness immediately.
- Avoid alcohol consumption.
- Monitor blood glucose levels.
Serious warnings
- Risk of myopathy/rhabdomyolysis
- Liver enzyme monitoring recommended
- Increased risk of diabetes
Important Disclaimer
The Zuvamor FC Tablets professional information leaflet below is the property of Acino Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
